Literature DB >> 33750405

High concentrations of illicit stimulants and cutting agents cause false positives on fentanyl test strips.

Tracy-Lynn E Lockwood1, Alexandra Vervoordt2, Marya Lieberman2.   

Abstract

BACKGROUND: The opioid epidemic has caused an increase in overdose deaths which can be attributed to fentanyl combined with various illicit substances. Drug checking programs have been started by many harm reduction groups to provide tools for users to determine the composition of their street drugs. Immunoassay fentanyl test strips (FTS) allow users to test drugs for fentanyl by either filling a baggie or cooker with water to dissolve the sample and test. The antibody used in FTS is very selective for fentanyl at high dilutions, a characteristic of the traditional use of urine testing. These street sample preparation methods can lead to mg/mL concentrations of several potential interferents. We tested whether these concentrated samples could cause false positive results on a FTS.
METHODS: 20 ng/mL Rapid Response FTS were obtained from BTNX Inc. and tested against 4 different pharmaceuticals (diphenhydramine, alprazolam, gabapentin, and naloxone buprenorphine) and 3 illicit stimulants [cocaine HCl, methamphetamine, and 3,4-methylenedioxymethamphetamine (MDMA)] in concentrations from 20 to 0.2 mg/mL. The FTS testing pad is divided into 2 sections: the control area and the test area. Control and test area signal intensities were quantified by ImageJ from photographs of the test strips and compared to a threshold set by fentanyl at the FTS limit of detection.
RESULTS: False positive results indicating the presence of fentanyl were obtained from samples of methamphetamine, MDMA, and diphenhydramine at concentrations at or above 1 mg/mL. Diphenhydramine is a common cutting agent in heroin. The street sample preparation protocols for FTS use suggested by many online resources would produce such concentrations of these materials. Street samples need to be diluted more significantly to avoid interference from potential cutting agents and stimulants.
CONCLUSIONS: Fentanyl test strips are commercially available, successful at detecting fentanyl to the specified limit of detection and can be a valuable tool for harm reduction efforts. Users should be aware that when drugs and adulterants are in high concentrations, FTS can give a false positive result.

Entities:  

Keywords:  Drug testing; False positives; Fentanyl; Fentanyl test strip (FTS); Harm reduction; Opioid; Stimulant

Year:  2021        PMID: 33750405      PMCID: PMC7941948          DOI: 10.1186/s12954-021-00478-4

Source DB:  PubMed          Journal:  Harm Reduct J        ISSN: 1477-7517


  1 in total

1.  Regional Differences in the Drugs Most Frequently Involved in Drug Overdose Deaths: United States, 2017.

Authors:  Holly Hedegaard; Brigham A Bastian; James P Trinidad; Merianna R Spencer; Margaret Warner
Journal:  Natl Vital Stat Rep       Date:  2019-10
  1 in total
  3 in total

1.  Responding to a surge in overdose deaths: perspectives from US syringe services programs.

Authors:  Madeline C Frost; Elizabeth J Austin; Maria A Corcorran; Elsa S Briggs; Czarina N Behrends; Alexa M Juarez; Noah D Frank; Elise Healy; Stephanie M Prohaska; Paul A LaKosky; Shashi N Kapadia; David C Perlman; Bruce R Schackman; Don C Des Jarlais; Emily C Williams; Sara N Glick
Journal:  Harm Reduct J       Date:  2022-07-19

2.  Law Enforcement and Community Provision of Fentanyl Test Strips to People Who Use Drugs for Engagement and Referral to Services.

Authors:  Rebecca Olson; Patricia Case; Wilson R Palacios; Allie Hunter; Vanessa Lopes-McCoy; Traci C Green
Journal:  J Public Health Manag Pract       Date:  2022 Nov-Dec 01

3.  Infrequent detection of unintentional fentanyl use via urinalysis among people who regularly inject opioids in Sydney and Melbourne, Australia.

Authors:  Tina Lam; Monica J Barratt; Mark Bartlett; Julie Latimer; Marianne Jauncey; Sarah Hiley; Nico Clark; Dimitri Gerostamoulos; Linda Glowacki; Claude Roux; Marie Morelato; Suzanne Nielsen
Journal:  Addiction       Date:  2022-02-21       Impact factor: 7.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.